Trial Profile

A Randomized, Controlled, Open-label, Dose-exploration Study to Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients Who Have Not Received Antiviral Treatment Before.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir/lamivudine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/tenofovir (Primary) ; Lipovirtide (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Sponsors Shanxi Kangbao Biological Product

16 Aug 2024 Planned End Date changed from 30 Oct 2024 to 30 Dec 2024.
16 Aug 2024 Planned primary completion date changed from 20 Jun 2024 to 20 Dec 2024.
20 Dec 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com